This additional effect of exemestane on the CYP19 promoter level is not present during therapy with letrozole, according to our findings presented here and may, at least partly, explain why exemestane may cause clinical responses in breast cancer patients who experience disease progression while on treatment with a non-steroidal aromatase inhibitor. This evidence concerns the gene CYP19A1 and breast carcinoma.